CA2233445A1 - Utilisation de 2-mercaptoethanolamine (2-mea) et de composes aminothiols similaires, en combinaison avec du 3,5-diisopropyl-salicylate de cuivre (ii) et des composes similaires, pour le traitement et la prevention de differentes maladies - Google Patents
Utilisation de 2-mercaptoethanolamine (2-mea) et de composes aminothiols similaires, en combinaison avec du 3,5-diisopropyl-salicylate de cuivre (ii) et des composes similaires, pour le traitement et la prevention de differentes maladies Download PDFInfo
- Publication number
- CA2233445A1 CA2233445A1 CA002233445A CA2233445A CA2233445A1 CA 2233445 A1 CA2233445 A1 CA 2233445A1 CA 002233445 A CA002233445 A CA 002233445A CA 2233445 A CA2233445 A CA 2233445A CA 2233445 A1 CA2233445 A1 CA 2233445A1
- Authority
- CA
- Canada
- Prior art keywords
- mea
- administration
- cells
- patient
- transfer factor
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/60—Salicylic acid; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/145—Amines having sulfur, e.g. thiurams (>N—C(S)—S—C(S)—N< and >N—C(S)—S—S—C(S)—N<), Sulfinylamines (—N=SO), Sulfonylamines (—N=SO2)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/42—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum viral
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Immunology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Virology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Transplantation (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- AIDS & HIV (AREA)
- Tropical Medicine & Parasitology (AREA)
- Molecular Biology (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
L'invention concerne de nouvelles compositions et applications de 2-mercaptoéthanolamine (2-MEA) et d'aminothiols similaires, en combinaison avec du 3,5-diisopropyl-salicylate de cuivre (II). Ces compositions sont utilisées seules ou en association avec d'autres facteurs, agents ou procédés physiques, chimiques et/ou biologiques. Il peut s'agir de précurseurs, d'intermédiaires, de produits finis, de catalyseurs, de promoteurs et/ou d'autres facteurs, agents ou procédés mis en jeu directement ou indirectement depuis l'application initiale de la composition jusqu'à l'obtention du résultat recherché.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US428195P | 1995-09-25 | 1995-09-25 | |
US60/004,281 | 1995-09-25 |
Publications (1)
Publication Number | Publication Date |
---|---|
CA2233445A1 true CA2233445A1 (fr) | 1997-04-03 |
Family
ID=21710013
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CA002233015A Abandoned CA2233015A1 (fr) | 1995-09-25 | 1996-09-25 | Utilisation therapeutique de serums d'animaux, en particulier du cheval, pour le traitement du sida, du cancer et d'autres maladies virales et bacteriennes |
CA002233445A Abandoned CA2233445A1 (fr) | 1995-09-25 | 1996-09-25 | Utilisation de 2-mercaptoethanolamine (2-mea) et de composes aminothiols similaires, en combinaison avec du 3,5-diisopropyl-salicylate de cuivre (ii) et des composes similaires, pour le traitement et la prevention de differentes maladies |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CA002233015A Abandoned CA2233015A1 (fr) | 1995-09-25 | 1996-09-25 | Utilisation therapeutique de serums d'animaux, en particulier du cheval, pour le traitement du sida, du cancer et d'autres maladies virales et bacteriennes |
Country Status (5)
Country | Link |
---|---|
EP (2) | EP0853486A4 (fr) |
JP (1) | JPH11514990A (fr) |
AU (2) | AU6999096A (fr) |
CA (2) | CA2233015A1 (fr) |
WO (2) | WO1997011666A2 (fr) |
Families Citing this family (17)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5994409A (en) | 1997-12-09 | 1999-11-30 | U.S. Bioscience, Inc. | Methods for treatment of neuro--and nephro--disorders and therapeutic toxicities using aminothiol compounds |
US6384259B1 (en) | 1998-11-16 | 2002-05-07 | Medimmune Oncology, Inc. | Stable amorphous amifostine compositions and dosage form |
WO2001024803A2 (fr) * | 1999-10-04 | 2001-04-12 | John Carter | Compositions pharmaceutiques et leur utilisation |
US7927612B2 (en) | 2000-01-19 | 2011-04-19 | Baofa Yu | Combinations and methods for treating neoplasms |
US6811788B2 (en) | 2000-01-19 | 2004-11-02 | Baofa Yu | Combinations and methods for treating neoplasms |
US6506413B1 (en) * | 2001-04-30 | 2003-01-14 | Joseph C. Ramaekers | Compositions for treating animal diseases and syndromes |
US7053072B2 (en) | 2001-05-11 | 2006-05-30 | Medimmune Oncology, Inc. | Methods for the administration of amifostine and related compounds |
FR2825923B1 (fr) * | 2001-06-15 | 2006-04-07 | Oreal | Inhibiteur de no-synthase et utilisations |
KR20030077743A (ko) * | 2002-03-26 | 2003-10-04 | 변현규 | In½ |
US7629333B2 (en) | 2002-03-29 | 2009-12-08 | Medimmune, Llc | Stable amorphous amifostine compositions and methods for the preparation and use of same |
WO2004024129A1 (fr) * | 2002-09-10 | 2004-03-25 | Samir Chachoua | Therapie induisant une remission |
GB2398497A (en) * | 2003-02-19 | 2004-08-25 | Walcom Animal Science | Composition for improving immunity of animals |
US9125874B2 (en) | 2007-11-30 | 2015-09-08 | The Ramaekers Family Trust | Administration of transfer factor for improving reproductive health |
CN101138634A (zh) | 2006-09-07 | 2008-03-12 | 于保法 | 用于治疗肿瘤的组合物 |
EP2278984A4 (fr) | 2007-11-30 | 2013-02-27 | Ramaekers Family Trust | Compositions et procédés d'amélioration de la fertilité |
US20110311557A1 (en) * | 2009-02-11 | 2011-12-22 | Martin Heath Bluth | Reciprocal serum/plasma exchange for the treatment of cancer |
CA2968853A1 (fr) | 2014-11-26 | 2016-06-02 | Baofa Yu | Chimio-immunotherapie haptene-amelioree par chimio-immunotherapie intratumorale personnalisee par incision ultra-minimale |
Family Cites Families (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4228127A (en) * | 1978-10-06 | 1980-10-14 | International Radioimmune Systems, Inc. | Kit for detecting human chorionic gonadotropin |
US4952607A (en) * | 1982-05-27 | 1990-08-28 | International Copper Research Association, Inc. | Copper complex for treating cancer |
US5057314A (en) * | 1988-09-30 | 1991-10-15 | Whitfill Craig E | Low molecular weight antiviral factors |
US5310653A (en) * | 1989-10-24 | 1994-05-10 | Board Of Regents, The University Of Texas System | Tumor marker protein and antibodies thereto for cancer risk assessment or diagnosis |
US5488042A (en) * | 1992-03-13 | 1996-01-30 | Arch Development Corporation | Method for protection against genotoxic mutagenesis |
DE4236069A1 (de) * | 1992-10-26 | 1994-04-28 | Werner Dr Bergmann | Arzneimittel, insbesondere für orale Einnahme |
AU7098694A (en) * | 1993-06-07 | 1995-01-03 | Center For Special Immunology | Adoptive immune reconstitution treatment for patients with acquired immunodeficiencies |
-
1996
- 1996-09-25 WO PCT/IB1996/001059 patent/WO1997011666A2/fr not_active Application Discontinuation
- 1996-09-25 EP EP96932773A patent/EP0853486A4/fr not_active Withdrawn
- 1996-09-25 JP JP9513260A patent/JPH11514990A/ja not_active Ceased
- 1996-09-25 WO PCT/IB1996/001115 patent/WO1997011667A2/fr not_active Application Discontinuation
- 1996-09-25 AU AU69990/96A patent/AU6999096A/en not_active Abandoned
- 1996-09-25 CA CA002233015A patent/CA2233015A1/fr not_active Abandoned
- 1996-09-25 AU AU71431/96A patent/AU7143196A/en not_active Abandoned
- 1996-09-25 EP EP96931214A patent/EP0858327A2/fr not_active Withdrawn
- 1996-09-25 CA CA002233445A patent/CA2233445A1/fr not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
EP0858327A2 (fr) | 1998-08-19 |
AU7143196A (en) | 1997-04-17 |
CA2233015A1 (fr) | 1997-04-03 |
WO1997011667A2 (fr) | 1997-04-03 |
EP0853486A2 (fr) | 1998-07-22 |
WO1997011667A3 (fr) | 1997-06-12 |
JPH11514990A (ja) | 1999-12-21 |
AU6999096A (en) | 1997-04-17 |
WO1997011666A2 (fr) | 1997-04-03 |
EP0853486A4 (fr) | 2001-09-26 |
WO1997011666A3 (fr) | 1997-06-19 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CA2233445A1 (fr) | Utilisation de 2-mercaptoethanolamine (2-mea) et de composes aminothiols similaires, en combinaison avec du 3,5-diisopropyl-salicylate de cuivre (ii) et des composes similaires, pour le traitement et la prevention de differentes maladies | |
EP2286832B1 (fr) | Compositions bactériennes pour le traitement du cancer | |
US20200384040A1 (en) | Use of bacteroides fragilis in preparation of medicament for treating and preventing tumor | |
Renoux et al. | Potentiation of T-cell mediated immunity by levamisole. | |
KR100955973B1 (ko) | 세포 사멸을 조절하는 세포독성인자 | |
EP0726772B1 (fr) | Procede de sensibilisation de cellules cancereuses destinees a la lyse induite par cellules "tueuses" | |
Fang et al. | Enhanced bacterial tumor delivery by modulating the EPR effect and therapeutic potential of Lactobacillus casei | |
Teixeira et al. | Malignant, non-Hodgkin's lymphomas in Trypanosoma cruzi-infected rabbits treated with nitroarenes | |
Xie et al. | Research progress in inducing immunogenic cell death of tumor cells | |
US6258847B1 (en) | Use of 2-mercaptoethanolamine (2-MEA) and related aminothiol compounds and copper(II)-3,5 di-isopropyl salicylates and related compounds in the prevention and treatment of various diseases | |
Farber | Clinical and biological studies with actinomycins | |
WO2017222295A1 (fr) | Composition pour la prévention et le traitement du virus de la grippe, comprenant des bactéries lactiques dérivées du kimchi et de la pâte de soja comme ingrédient actif | |
UA79952C2 (en) | MYCOBACTERIUM w APPLICATIONS FOR CANCER TREATMENT | |
Malkov et al. | Antitumor features of Bacillus oligonitrophilus KU-1 strain | |
AU7214700A (en) | Use of 2-mercaptoethanolamine (2-mea) and related aminothiol compounds and copper (II)-3,5 di-isopropyl salicylates and related compounds in the prevention and treatment of various diseases | |
Erciyas | Murrembeena (AU) | |
JPS6212721A (ja) | 椎茸霊芝の製造法 | |
Nowotny et al. | Studies on host defenses enhanced by endotoxins: a brief review | |
RU2587332C1 (ru) | Способ лечения больных деструктивными формами туберкулеза легких | |
RU2207127C1 (ru) | Способ лечения экспериментального туберкулеза | |
OKURA et al. | Effect of forphenicinol on the production of Ia-positive macrophages in mice with or without L1210 leukemia and on the growth of L1210 in immunized mice | |
Miura et al. | Effects of levamisole administration on treatment with 6-mercaptopurine riboside of mice bearing L1210 leukemia cells | |
Hoffmann et al. | Antiproliferative effect of retinoids and interferon α in combination with irradiation on human tumor cell lines | |
Adler et al. | Effect of liposomal allogeneic melanoma vaccine with IL-2 on cellular immune responses | |
Becker et al. | Antiphospholipid syndrome associated with immunotherapy for patients with melanoma |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
EEER | Examination request | ||
FZDE | Dead |